Breast cancer research program

Active Awarded Last action

Contract number
HT942726FE020
Awardee
Awarding agency
Obligated
$439,016

Award facts

Contract value 48% obligated
$910,210.61 Current and potential, with all options
Completion date 64% complete
Current and potential, with all options
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Reston, VA 20190, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00001 $0
Original award $439,016

About this award

The Defense Health Agency awarded a delivery order to Leidos, Inc. on March 2, 2026, carrying a $910,210.61 ceiling for the Breast Cancer Research Program. The order is cost-plus-fixed-fee, runs through March 31, 2027, and was issued with no set-aside. Place of performance is Reston, VA 20190. Leidos is a large, unrestricted prime without SBA small business designations.

Quick answers

Who was awarded contract HT942726FE020?

HT942726FE020 was awarded to Leidos, Inc. by Defense Health Agency (Department of Defense) on March 2, 2026.

How much is contract HT942726FE020 worth?

The government has obligated $439,016 on HT942726FE020. Its current value, with exercised options, is $910,211.

Is contract HT942726FE020 an order under another contract?

Yes. HT942726FE020 is a delivery order under HT942523D0002, an indefinite delivery contract.

Was contract HT942726FE020 competed?

The extent of competition for HT942726FE020 was full and open competition.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award